410PPhase I study of the investigational, oral pan-RAF kinase inhibitor TAK-580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): Final analysis

A.J. Olszanski, R. Gonzalez, P. Corrie, A.C. Pavlick, M. Middleton, P. Lorigan, R. Plummer, S. Skaria, C. Herbert, M. Gore, S. Agarwala, A. Daud, S. Zhang, B. Bahamon, L. Rangachari, E. Hoberman, M. Kneissl, D. Rasco

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalAnnals of Oncology
Issue numbersuppl_5
Publication statusPublished - 1 Sept 2017

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Cite this